Royalty Pharma (RPRX) Stock Price, News & Analysis

Company Overview

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors. Royalty Pharma’s portfolio spans multiple therapeutic areas and stages of product life cycles; revenues are derived from sales of underlying drugs in markets around the world. Its business model is positioned to provide liquidity to biopharma owners while assuming the commercial and regulatory risk associated with future product sales.

Founded by Pablo Legorreta and headquartered in New York, Royalty Pharma completed a public listing on the Nasdaq under the ticker RPRX in 2020. The company operates globally, collecting royalties generated by product sales in multiple geographies and partnering with a wide range of industry participants. Pablo Legorreta, the company’s founder and long-time leader, has been a central figure in Royalty Pharma’s strategy of building a large, diversified portfolio of biopharma royalty assets.

Key Stats

• Today's Range: $49.74 to $51.65
• 50-Day Range: $45.15 to $50.77
• 52-Week Range: $32.15 to $51.65
• Volume: 3.89 million shs
• Average Volume: 3.03 million shs
• Market Capitalization: $29.28 billion
• P/E Ratio: 37.60
• Dividend Yield: 1.85%
• Price Target: $50.33
• Consensus Rating: Buy

Royalty Pharma Stock Analysis - MarketRank™

Royalty Pharma scored higher than 72% of companies evaluated by MarketBeat, and ranked 187th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Royalty Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Royalty Pharma is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Royalty Pharma has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 6.30%

Earnings Growth

Earnings for Royalty Pharma are expected to grow by 6.30% in the coming year, from $5.08 to $5.40 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Royalty Pharma is 37.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.23.

Price to Earnings Ratio vs. Sector

The P/E ratio of Royalty Pharma is 37.60, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.35.

Price to Earnings Growth Ratio

Royalty Pharma has a PEG Ratio of 3.22. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Royalty Pharma has a P/B Ratio of 3.02. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.57% of the float of Royalty Pharma has been sold short.

Short Interest Ratio / Days to Cover

Royalty Pharma has a short interest ratio ("days to cover") of 4.36.

Change versus previous month

Short interest in Royalty Pharma has recently increased by 4.26%, indicating that investor sentiment is decreasing.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

Royalty Pharma pays a meaningful dividend of 1.86%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Royalty Pharma has been increasing its dividend for 5 years.

Dividend Coverage

The dividend payout ratio of Royalty Pharma is 69.63%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Royalty Pharma will have a dividend payout ratio of 17.41% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.4 / 5
• News Sentiment: 0.96

News Sentiment

Royalty Pharma has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Royalty Pharma this week, compared to 5 articles on an average week.

Search Interest

9 people have searched for RPRX on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.

MarketBeat Follows

16 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 220% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Royalty Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,624,902.00 in company stock.

Percentage Held by Insiders

18.84% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RPRX Stock Analysis - Frequently Asked Questions

How have RPRX shares performed this year?

Royalty Pharma's stock was trading at $38.64 at the start of the year. Since then, RPRX stock has increased by 31.4% and is now trading at $50.7650.

How were Royalty Pharma's earnings last quarter?

Royalty Pharma PLC (NASDAQ:RPRX) issued its earnings results on Wednesday, February, 11th. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.33 by $0.13. The biopharmaceutical company had revenue of $621.99 million for the quarter, compared to the consensus estimate of $839.97 million. Royalty Pharma had a trailing twelve-month return on equity of 28.21% and a net margin of 32.38%.
Read the conference call transcript.

When did Royalty Pharma IPO?

Royalty Pharma (RPRX) raised $1.9 billion in an initial public offering on Tuesday, June 16th 2020. The company issued 70,000,000 shares at a price of $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank served as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers.

Who are Royalty Pharma's major shareholders?

Top institutional investors of Royalty Pharma include Swedbank AB (2.01%), Hsbc Holdings PLC (0.27%), Bank of New York Mellon Corp (0.23%) and Sumitomo Mitsui Trust Group Inc. (0.22%). Insiders that own company stock include Avara Management Ltd, Pablo G Legorreta, Rory B Riggs, Terrance P Coyne, Marshall Urist and George W Lloyd.
View institutional ownership trends.

How do I buy shares of Royalty Pharma?

Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Royalty Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Royalty Pharma investors own include Bristol Myers Squibb (BMY), Chevron (CVX), McKesson (MCK), Comcast (CMCSA), NVIDIA (NVDA), Charles Schwab (SCHW) and Invesco QQQ (QQQ).

Company Calendar

• Last Earnings: 2/11/2026
• Record date for 3/10 Dividend: 2/20/2026
• Ex-Dividend for 3/10 Dividend: 2/20/2026
• Dividend Payable: 3/10/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/06/2026
• Bank of America Global Healthcare Conference 2026: 5/13/2026
• Record date for 6/10 Dividend: 5/15/2026
• Ex-Dividend for 6/10 Dividend: 5/15/2026
• Dividend Payable: 6/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:RPRX
• CIK: 1802768
• Web: www.royaltypharma.com
• Phone: 212-883-0200
• Fax: N/A
• Employees: 80
• Year Founded: 1996

Price Target and Rating

• Average Price Target for Royalty Pharma: $50.33
• High Price Target: $63.00
• Low Price Target: $42.00
• Potential Upside/Downside: -0.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.35
• Trailing P/E Ratio: 37.60
• Forward P/E Ratio: 9.99
• P/E Growth: 3.22
• Net Income: $770.95 million
• Net Margins: 32.38%
• Pretax Margin: 55.68%
• Return on Equity: 28.21%
• Return on Assets: 14.55%

Debt

• Debt-to-Equity Ratio: 0.88
• Current Ratio: 2.40
• Quick Ratio: 2.40

Sales & Book Value

• Annual Sales: $2.38 billion
• Price / Sales: 12.31
• Cash Flow: $4.81 per share
• Price / Cash Flow: 10.56
• Book Value: $16.83 per share
• Price / Book: 3.02

Miscellaneous

• Outstanding Shares: 576,860,000
• Free Float: 468,177,000
• Market Cap: $29.28 billion
• Optionable: Optionable
• Beta: 0.40